Back to Search
Start Over
Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias
- Source :
- Blood; September 2024, Vol. 144 Issue: 11 p1206-1220, 15p
- Publication Year :
- 2024
-
Abstract
- •JNJ-75276617 shows preclinical activity in KMT2A- or NPM1-altered leukemia, synergizing with gilteritinib, venetoclax, and azacitidine.•Antiproliferative activity in cells harboring meninmutations M327I and T349M is due to a unique binding mode.
Details
- Language :
- English
- ISSN :
- 00064971 and 15280020
- Volume :
- 144
- Issue :
- 11
- Database :
- Supplemental Index
- Journal :
- Blood
- Publication Type :
- Periodical
- Accession number :
- ejs66738028
- Full Text :
- https://doi.org/10.1182/blood.2023022480